

## **Product datasheet for TA385163**

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## Rel B (RELB) Rabbit Monoclonal Antibody [Clone ID: R07-9J3]

### **Product data:**

**Product Type:** Primary Antibodies

Clone Name: R07-9J3
Applications: IP, WB

Recommended Dilution: WB: 1/1000

IP: 1/20

Reactivity: Human, Mouse, Rat

Host: Rabbit Isotype: IgG

Clonality: Monoclonal

**Immunogen:** A synthetic peptide of human Rel B

Formulation: 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40% Glycerol, 0.01% Sodium azide and 0.05% BSA

**Concentration:** lot specific

Purification:Affinity PurifiedConjugation:Unconjugated

Storage: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Stability: 1 year

Predicted Protein Size: Calculated MW: 62 kDa; Observed MW: 62 kDa

**Gene Name:** RELB proto-oncogene, NF-kB subunit

Database Link: Entrez Gene 5971 Human

Q01201




#### Background:

Swiss-Prot Acc.Q01201.NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NFkappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52. Is required for both T and B lymphocyte maturation and function (PubMed:26385063).


Synonyms: I-REL; IREL; REL-B

# **Product images:**



Western blot analysis of Rel B in 3T3, C6 lysates using Rel B antibody.





Western blot analysis of Rel B in Raji lysates using Rel B antibody.